27 results
Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Thumbnail

D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age

Thumbnail

D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis

Thumbnail

D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience

Thumbnail

D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital

Thumbnail

D3.48 - The delabeling of beta-lactam allergy does not change the antibiotic prescribing profile or alerts in Primary Care. The experience of a General Hospital

Thumbnail

D3.53 - A retrospective audit of NSAID hypersensitivity in children and young people in a tertiary paediatric allergy centre

Thumbnail

D3.55 - Synthetic folic acid allergy

Thumbnail

D3.47 - Implementing Penicillin Delabelling in an Inpatient setting

Thumbnail

D3.49 - Clinical significance and safety of provocation test for drug allergy diagnosis in outpatient unit: A real world observational study

Thumbnail

D3.50 - Penicillin-allergic labelled patients with a PEN-FAST score of 0 could safely be de-labelled by non-allergists

Thumbnail

D3.51 - Using PEN-FAST score to guide prescription of alternative beta-lactam in penicillin-allergic patients by non-allergists

Thumbnail

D3.54 - Hypersensitivity reactions during therapy with platinum compounds and taxanes – who can benefit from consulting an allergist?